GT Biopharma, Inc.
GTBPDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Temozolomide | Phase 3 | Glioblastoma | - | - |
Frequently asked questions
What is in GT Biopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in GT Biopharma, Inc.'s (GTBP) pipeline across Phase 3. Its lead program is Temozolomide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GT Biopharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for GT Biopharma, Inc. (GTBP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GTBP biotech catalysts?→
Add GTBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GT Biopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.